Reappraisal of human CYP isoforms involved in imipramine N- demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1199-1210

  Koyama, Eriko ^a   Chiba, Kan ^b   Tani, Masanao ^a   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYDESIPRAMINE; 2 HYDROXYIMIPRAMINE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DRUG METABOLITE; FURAFYLLINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMIPRAMINE; MEPHENYTOIN; MIANSERIN; N DEMETHYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; QUINIDINE; RECOMBINANT ENZYME; TROLEANDOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; MICHAELIS CONSTANT; PHENOTYPE; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROXYLATION; IMIPRAMINE; LIVER; MALE; MEPHENYTOIN; MICROSOMES; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0030976985     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. AKAIKE, H.: A new look at the statistical model identification. IEEE. Trans. Automat. Contr. 19: 716-723, 1974.
2. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. AND BIRKETT, D. J.: Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol. 38: 131-137, 1994.
3. BRØSEN, K. AND GRAM, L. F.: First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 43: 400-406, 1988.
4. BRØSEN, K., GRAM, L. F., KLYSNER, R. AND BECH, P.: Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur. J. Clin. Pharmacol. 30: 43-49, 1986a.
5. BRØSEN, K., OTTON, S. V. AND GRAM, L. F.: Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 40: 543-549, 1986b.
6. BRØSEN, K., ZEUGIN, T. AND MEYER, U. A.: Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49: 609-617, 1991.
7. CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. AND ISHIZAKI, T.: Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266: 52-59, 1993a.
8. MP) activity in human liver samples obtained as surgical waste from Japanese patients. Drug. Metab. Dispos. 21: 747-749, 1993b.
9. CHIBA, K., SAITOH, A., KOYAMA, E., TANI, M., HAYASHI, M. AND ISHIZAKI, T.: The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br. J. Clin. Pharmacol. 37: 237-242, 1994.
10. DAHL, M.-L. AND BERTILSSON, L.: Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70, 1993.
11. DALY, A. K., BROCKMÖLLER, J., BROLY, F., EICHELBAUM, M., EVANS, W. E., GONZALEZ, F. J., HUANG, J.-D., IDLE, J. R., INGELMAS-SUNDBERG, M., ISHIZAKI, T., JACQZ-AIGRAIN, E., MEYER, U. A., NEBERT, D. W., STEEN, V. M., WOLF, C. R. AND ZANGER, U. M.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201, 1996.
12. dE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. AND GOLDSTEIN, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46: 594-598, 1994a.
13. dE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. A. AND GOLDSTEIN, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15149-15422, 1994b.
14. EILERS, R.: Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clin. Pharmacokinet. 29: 442-450, 1995.
15. GOLDSTEIN, J. A. AND DE MORAIS, S. M. F.: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
16. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM, B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
17. HORAI, Y., NAKANO, M., ISHIZAKI, T., ISHIKAWA, K., ZHOU, H.-H., ZHOU, B.-J., LIAO, C.-L. AND ZHANG, L.-M.: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207, 1989.
18. IMAOKA, S., YAMADA, T., HIROI, T., HAYASHI, K., SAKAKI, T., YABUSAKI, Y. AND FUNAE, Y.: Multiple forms of human P450 expressed in Saccharomyces cerevisiae: Systematic characterization and comparison with those of the rat. Biochem. Pharmacol. 51: 1041-1050, 1996.
19. KOBAYASHI, S., MURRAY, S., WATSON, D., SESARDIC, D., DAVIES, D. S. AND BOOBIS, A. R.: The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine is the inverse of that in man. Biochem. Pharmacol. 38: 2795-2799, 1989.
20. KOYAMA, E., KIKUCHI, Y., ECHIZEN, H., CHIBA, K. AND ISHIZAKI, T.: Simultaneous high-performance liquid electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites and imipramine N-oxide in human plasma and urine: Preliminary application to oxidation pharmacogenetics. Ther. Drug Monit. 15: 224-235, 1993.
21. KOYAMA, E., SOHN, D.-R., SHIN, S.-G., CHIBA, K., SHIN, J.-G., KIM, Y.-H., ECHIZEN, H. AND ISHIZAKI, T.: Metabolic disposition of imipramine in Oriental subjects: Relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J. Pharmacol. Exp. Ther. 271: 860-867, 1994.
22. KOYAMA, E., TANAKA, T., CHIBA, K., KAWAKATSU, S., MORINOBU, S., TOTSUKA, S. AND ISHIZAKI, T.: Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J. Clin. Psychopharmacol. 16: 286-293, 1996.
23. KUNZE, K. L. AND TRAGER, W. F.: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6: 649-656, 1993.
24. LEMOINE, A., GAUTIER, J. C., AZOULAY, D., KLFEK, L., BELLOC, C., GUENGERICH, F. P., MAUREL, P., BEAUNE, P. AND LEROUX, J. P.: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43: 827-832, 1993.
25. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
26. NAKAMURA, K., GOTO, F., RAY, W. A., MCALLISTER, C. B., JACQZ, E., WILKINSON, G. R. AND BRANCH, R. A.: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38: 402-408, 1985.
27. OHMORI, S., TAKEDA, S., KITADA, M., RIKIHISA, T., KIUCHI, M. AND KANAKUBO, Y.: Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol. Pharm. Bull. 16: 571-575, 1993.
28. PEARCE, R. E., RODRIGUKS, A. D., GOLDSTEIN, J. A. AND PARKINSON, A.: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277: 805-816, 1996.
29. PRESKORN, S. H., BURKE, M. J. AND FAST, G. A.: Therapeutic drug monitoring. Principles and practice. Psychiatr. Clin. North Am. 16: 611-645, 1993.
30. RUDORFER, M. V. AND POTTER, W. Z.: Pharmacokinetics of antidepressants. In Psychopharmacology: The Third Generation Progress, ed. by H. Y. Meltzer. pp. 1353-1363, Raven Press, New York, 1987.
31. SALLEE, F. R. AND POLLOCK, B. G.: Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18: 346-364, 1990.
32. SCHMIDER, J., GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S. AND SHADER, R. I.: N-Demethylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275: 592-597, 1995.
33. SHIMADA, T., YAMAZAKI, H., MIURA, M., INUI, Y. AND GUENGERICH, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
34. SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. AND KORZEKWA, K. R.: Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33: 6450-6455, 1994.
35. SKJELBO, E. AND BRØSEN, K: Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34: 256-261, 1992.
36. SKJELBO, E., BRØSEN, K., HALLAS, J. AND GRAM, L. F.: The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49: 18-23, 1991.
37. SPINA, E., BIRGERSSON, C., VON BAHR, C., ERICSSON, O., MELLSTRÖM, B., STEINER, E. AND SJÖQVIST, F.: Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin. Pharmacol. Ther. 36: 677-682, 1984.
38. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. AND MINERS, J. O.: Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265: 401-407, 1993.
39. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. AND GUZELIAN, P. S.: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82: 6310-6314, 1985.
40. WILKINSON, G. R., GUENGERICH, J. P. AND BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43: 53-76, 1989.
41. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Critical Rev. Toxicol. 22: 1-21, 1992.
42. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. AND VANDENBRANDEN, M.: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993.
43. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. AND UNO, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio. Dyn. 4: 879-885, 1981.
44. YASUMORI, T., MURAYAMA, N., YAMAZOE, Y. AND KATO, R.: Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin. Pharmacol. Ther. 47: 313-322, 1990.
45. YASUMORI, T., NAGATA, K., YANG, S. K., CHEN, L.-S., MURAYAMA, N., YAMAZOE, Y. AND KATO, R.: Cytochrome P450 mediated metabolism of diazepam in human and rat: Involvement of human CYP2C in N-demethylation in concentration-dependent manner. Pharmacogenetics 3: 291-301, 1993.